Mirataz 20 mg/ml - Transdermal ointment

Authorised

• Mirtazapine hemihydrate

Product identification

Medicine name:

Mirataz 20 mg/ml - Transdermal ointment

Active substance:

Mirtazapine hemihydrate

Target species:

Cat

Route of administration:

Transdermal use

Product details

Active substance and strength:

Mirtazapine hemihydrate 0.02 gram(s) / 1.00 Tube

Pharmaceutical form:

Transdermal ointment

Withdrawal period by route of administration:

Transdermal use:

•

Cat

Anatomical therapeutic chemical veterinary (ATCvet) codes:

ON06AX11

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom (Northern Ireland)

Package description:

Packaging:Tube (Alu, within child resistant cardboard carton), Package_size:1 tube,

Content:5 g

Packaging:Tube (Alu within plastic bottle), Package_size:1 tube, Content:5 g

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Dechra Regulatory B.V

Marketing authorisation date:

10/12/2019

Manufacturing sites for batch release:

| ty |
|----|
| |

Authorisation number:

European Commission

This information is not available for this product.

Date of authorisation status change:

1/02/2022

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 15/11/2022

Download

ema-puar-mirataz-v-4733-par-en.pdf

Source URL: https://medicines.health.europa.eu/veterinary/60000003654